Enanta Pharmaceuticals Announces IPO pricing
Enanta Pharmaceuticals, a research and development-focused biotechnology company has announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $14.00 per share. Enanta is backed by Advent International, AlpInvest Partners, Alpha Associates, BioVentures Investors, Global Biomedical Partners, Lancet Capital, Oxford Bioscience Partners, TVM Capital and Wheatley Partners.
21 March 2013•3 mins read
